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IntroductIon
Hepcidin and iron metabolism
Iron is an essential element for nearly all living organisms. 
Iron is a key component of oxygen storage and transporting 
proteins, such as hemoglobin and myoglobin, and of many 
enzymes that catalyze oxidation-reduction reactions necessary 
to generate energy and produce various metabolic intermediates 
for host defense1-3.
In all species, the concentration of iron in biological 
fluids is tightly regulated to provide iron as needed and to 
avoid toxicity, since iron excess can lead to the generation of 
reactive oxygen species (ROS), and decreased iron levels can 
lead to anemia4,5. Thus, maintenance of body iron stores is 
essential, because many human diets contain iron sufficient 
only to replace the small iron losses. When iron intake is 
more abundant, apparently iron absorption is appropriately 
controlled 6,7.
Iron deficiency may occur by inadequate dietary intake, by 
increased physiological needs of the nutrient, and/or by increased 
losses, which may lead to anemia
Anemia is the most widespread nutritional disorder in the 
world, affecting mainly women of childbearing age and children 
under two years of age 8. The same scenario is described in 
Brazilian studies 9-12. Data from the last National Survey on 
Children and Women Health revealed that 20.9% of Brazilian 
children and 29.4% of women have anemia13.
For this reason, there is great interest in investigating effective 
methods for the diagnosis of iron deficiency anemia.
Recent studies have evaluated the use of hepcidin as a 
biomarker for the regulation of iron metabolism. Hepcidin has 
evolved as the primary regulator of iron homeostasis and a 
probable mediator of anemia of chronic disease and inflamma-
tion. This role has been widely demonstrated in a number of 
recent studies14-18, and there is enormous interest in quantifying 
circulating hepcidin levels in clinical samples19.
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Abstract
Iron deficiency anemia is the most prevalent nutritional disorder in the world. Information on the 
metabolism of hepcidin and its possible significance as a biochemical parameter in iron deficiency 
anemia is reported in this review, which was based on a survey of the databases PubMed and LILACS 
for articles published between 2006 and 2010 on hepcidin as a biomarker for the regulation of 
iron metabolism. The literature search returned 35 studies published in international journals and 
one study on the subject in a Brazilian journal. Hepcidin production is homeostatically regulated by 
anemia and hypoxia. When oxygen delivery is inadequate, hepcidin levels decrease. Consequently, 
more iron is made available from the diet and from the storage pool in macrophages and hepatocytes. 
Hepcidin binds to ferroportin, regulating iron release into plasma. When hepcidin concentrations are 
low, ferroportin molecules are displayed on the plasma membrane and release iron. When hepcidin 
levels increase, hepcidin binds to ferroportin molecules inducing their internalization and degradation, 
and iron release is decreased progressively. Apparently, the development of diagnosis and therapy for 
anemia based on the bioindicator hepcidin may provide a more effective approach. Epidemiological 
studies are needed to demonstrate the relevance of hepcidin to the differential diagnosis of anemia, 
including sampling protocols for analysis, with standardization similar to that used in other biochemical 
assessments, and establishment of cutoff points for urinary and plasma expression of this peptide. 
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objectIve
The objective of this study was to gather information on 
the metabolism of hepcidin and its possible significance as a 
biochemical parameter for the assessment of the amount of iron 
absorbed in individuals with iron deficiency anemia.
methods 
A review of the literature was conducted based on a survey of 
the databases PubMed (National Library of Medicine’s Medline 
Biomedical Literature) and LILACS (Latin American and Caribbean 
Literature) for articles published between 2006 and 2009, using 
“hepcidin” as the subject heading (MeSH) and search descriptor, 
respectively. The literature search returned 501 articles on the 
subject; 500 studies published in international journals and one 
study in a Brazilian journal.
English- and Portuguese-language scientific publications that 
referred to hepcidin as a new biomarker for the regulation of 
iron metabolism were selected. Studies that related hepcidin to 
hemochromatosis, thalassemia, and anemia of chronic disease 
and inflammation were excluded, resulting in 36 studies: 35 
articles published in international journals and one article in a 
Brazilian journal 20.
Hepcidin expression related to iron deficiency anemia 
The discovery of hepcidin has given rise to a considerable 
number of studies on this topic. Hepcidin is a circulating peptide 
hormone composed of 25 amino acids, synthesized in the liver 
and detectable in blood and urine 3,21.
As the master regulator of systemic iron homeostasis, 
hepcidin coordinates the use and storage of this mineral in the 
body4. Hepcidin acts on the inhibition of intestinal iron absorption 
and iron release by macrophages and enterocytes16,17, and is a 
mediator in the cycle of iron absorption between the liver and 
intestine 22-24. 
Measurement of hepcidin concentrations can be used for 
different diagnoses of anemia, such as iron deficiency anemia, 
which is characterized by low levels of this hormone. In principle, 
hepcidin measurements could complement the most frequently 
used indicators of total body iron stores, such as serum iron and 
ferritin2,25,26, in addition to others such as transferrin receptor, 
transferrin saturation, and zinc protoporphyrin27.
Iron homeostasis is regulated by two main mechanisms: an 
intracellular mechanism, dependent on the amount of iron avai-
lable for the cell, and a systemic mechanism, in which hepcidin 
plays a crucial role 20,28.
Most of the iron absorbed from the diet or recycled from 
hemoglobin is intended for developing erythrocytes, whose 
production is increased in response to erythropoietic stimuli, 
such as blood loss or hypoxia. 
Hepcidin production is homeostatically regulated by anemia 
and hypoxia2,29, in addition to being regulated by inflammation 
and oxidative stress 30-33.
When oxygen delivery is inadequate, the homeostatic 
response is an increased production of erythrocytes. Hepcidin 
levels then decrease, as well as its inhibitory effects. Conse-
quently, more iron is made available from the diet and from the 
storage pool in macrophages and hepatocytes2.
Depending on the cell type, iron can be taken up by distinct 
pathways. Bioavailable iron in the diet is mostly present in both 
the ferric form (Fe3) and as heme. The uptake of Fe3 is mediated 
by duodenal cytochrome b reductase enzyme – Dcytb, reducing 
Fe3 to its ferrous form (Fe2), which is carried across the cell 
membrane by divalent metal transporter 1 – DMT1 2.
Inside the cell, absorbed Fe2 binds to ferritin heading to the 
basolateral membrane, where ferroportin is located, present in 
enterocytes, macrophages, and hepatocytes, which is a protein 
required for Fe2 transport into plasma20,34-36.
Hepcidin binds to ferroportin, regulating iron export into 
plasma. When hepcidin concentrations are low, ferroportin 
molecules are displayed on the plasma membrane and export 
iron. When hepcidin concentrations increase, hepcidin binds to 
ferroportin molecules inducing their internalization and degrada-
tion, and iron release is decreased progressively 3,36 (Figure 1).
Therefore, in healthy patients, hepatic hepcidin production 
is regulated by a feedback mechanism induced by circulating 
iron. Low levels of circulating hepcidin allow ferroportin to release 
iron into the bloodstream; elevated levels of hepcidin effectively 
reduce iron absorption in enterocytes by disabling the iron 
exporter ferroportin 37,38. Apparently, this mechanism observed 
in ferroportin present in enterocytes functions differently from 
ferroportin of macrophages or hepatocytes 34,39,40. 
Anemia induces a cascade of changes that individually or 
in combination suppress hepcidin expression. The decrease 
or absence of urinary hepcidin is the expected response in 
patients with iron deficiency anemia, such as patients with 
anemia caused by gastrointestinal blood loss. A study by Pak 
et al.41 found that anemia does not directly regulate hepcidin 
expression, but exerts its effects on this hormone and iron meta-
bolism through an as yet uncharacterized substance released 
during erythropoiesis. The specific mediators and pathways by 
Fpn = ferroportina (adaptado de Ganz 3).
Figure 1 - Mechanism of hepcidin-mediated cellular iron regulation
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which these elements influence hepcidin synthesis and release 
remain to be elucidated.  
The diagnosis of iron deficiency anemia within the context of 
anemia of chronic disease is commonly performed with routine 
biochemical parameters, such as transferrin saturation, C-reactive 
protein, and, less often, transferrin receptor and zinc protoporphyrin. 
Each has their own disadvantages. In contrast to the increased 
levels of hepcidin in anemia of chronic disease, both in vitro and the 
classic iron deficiency anemia in humans are associated with low 
hepcidin expression, which makes this hormone a potential marker 
for detection of iron deficiency anemia coexisting with anemia of 
chronic disease 42.
Anemia related to iron levels in humans and animal models 
highlights the importance of erythropoiesis in the regulation of 
hepcidin and the need to understand its molecular basis. Moreover, 
the development of diagnosis and therapy for anemia based on 
hepcidin may provide a more effective approach to prevent toxicity 
associated with iron overload 43.
Relationship of hepcidin with other molecules and biomarkers 
of iron nutritional status
Hepcidin concentration is apparently regulated by molecules 
such as transferrin receptor 2 – TfR2, HFE (product of a high-iron 
gene), and hemojuvelin – HJV. Studies in hepatocytes show that 
hepcidin responds to iron only when it is bound to transferrin, 
suggesting that the liver uses transferrin saturation as an iron sensor. 
At the cellular level, iron sensing appears to involve TfR2 and HFE. 
Patients with mutations in HFE do not produce hepcidin in response 
to oral iron as do normal individuals. In addition, other proteins 
are involved in hepcidin expression, including bone morphogenic 
proteins, among others 37
conclusIon
Recent studies have contributed to our knowledge of the major 
regulatory pathways of iron homeostasis in the body, highlighting the 
role that hepcidin plays in this process. Measurement of this hormone 
has the potential to become an important tool for diagnosis and treat-
ment of anemia and diseases caused by iron metabolism disorders.
The studies published so far are based on clinical trials, consisting 
of a limited number of cases. Epidemiological studies are needed 
to demonstrate the role of hepcidin in the differential diagnosis of 
anemia, including sampling protocols for analysis of hepcidin with 
standardization similar to that used in other biochemical assessments 
and establishment of cutoff points for urinary and plasma expression 
of this peptide. 
A better understanding of the precise interaction between ferro-
portin and hepcidin might pave the way for the development of new 
drugs that can alter hepcidin activity.
Furthermore, the development of accessible and accurate labo-
ratory tests is important to assess alterations in hepcidin expression 
in various populations. Although some methods for the production 
of recombinant hepcidin have been reported, further research is 
needed to provide pure hepcidin for the development of clinical 
trials in humans.
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